Abstract
Background:
Psychotic disorders are often difficult to treat with traditional neuroleptics. Sertindole is a new atypical neuroleptic with a broader CNS receptor profile.
Method:
Ten patients diagnosed with either schizophrenia or schizoaffective disorder were treated with sertindole for 18 months and observed for changes in Clinical Global Impression scale scores.
Results:
Nine patients experienced a reduction of symptoms after 12 months of treatment. Eight patients completed 18 months of treatment, all exhibiting overall improvement. Despite side effects of tiredness, weight gain, headache, nausea, and decreased ejaculatory volume, sertindole was generally well tolerated.
Conclusion:
Sertindole appears to be a useful treatment in psychotic disorders. It may present an advantage over traditional neuroleptics in the form of fewer extrapyramidal symptoms and improvement of negative symptoms.
Publication types
-
Case Reports
-
Clinical Trial
-
Clinical Trial, Phase III
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / pharmacology
-
Antipsychotic Agents / therapeutic use*
-
Delusions / drug therapy*
-
Delusions / psychology
-
Drug Administration Schedule
-
Female
-
Headache / chemically induced
-
Humans
-
Imidazoles / adverse effects
-
Imidazoles / pharmacology
-
Imidazoles / therapeutic use*
-
Indoles / adverse effects
-
Indoles / pharmacology
-
Indoles / therapeutic use*
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Psychiatric Status Rating Scales
-
Psychotic Disorders / drug therapy*
-
Psychotic Disorders / psychology
-
Receptors, Adrenergic, alpha / drug effects
-
Receptors, Dopamine D2 / drug effects
-
Receptors, Serotonin / drug effects
-
Schizophrenia / drug therapy*
-
Schizophrenic Psychology
-
Treatment Outcome
-
Weight Gain
Substances
-
Antipsychotic Agents
-
Imidazoles
-
Indoles
-
Receptors, Adrenergic, alpha
-
Receptors, Dopamine D2
-
Receptors, Serotonin
-
sertindole